SEC Form 6-K filed by Nymox Pharmaceutical Corporation
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of July, 2023
Commission File Number: 001-12033
| Nymox Pharmaceutical Corporation |
| (Translation of registrant’s name into English) |
Bay & Deveaux Streets, Nassau, The Bahamas
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On July 31, 2023, Nymox Pharmaceutical Corporation (the “Company”) issued a press release providing additional information concerning a recently discovered unauthorized award to Chris Riley of shares of stock, additional information regarding Mr. Riley’s termination, and additional information regarding the proposed transaction with the distributor. This press release is furnished as Exhibit 99.1 to this report on Form 6-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”), or otherwise subject to the liabilities of that section.
EXHIBIT INDEX
| Exhibit No. | Description | |
| Press Release of Nymox Pharmaceutical Corporation, dated July 31, 2023 |
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 31, 2023
| NYMOX PHARMACEUTICAL CORPORATION | ||||
|
|
|
| ||
|
| By: | /s/ Paul Averback |
| |
|
| Name: | Paul Averback | ||
|
| Title: | President and Chief Executive Officer | ||
| 3 |